H.R. 8992 aims to create a panel that will review requests for the Supreme Court to hear certain cases, known as certiorari petitions. This panel would likely evaluate the merits of these petitions before they are formally considered by the Court, potentially streamlining the process for deciding which cases should be taken up by the Supreme Court.
Supporters of H.R. 8992 argue that establishing a review panel could lead to a more efficient judicial process, ensuring that only the most significant cases reach the Supreme Court. This could help reduce the Court's workload and allow for a more focused examination of important legal issues.
Critics of H.R. 8992 express concerns that the creation of a certiorari review panel could undermine the traditional role of the Supreme Court and limit access to justice for certain cases. There are fears that such a panel may introduce additional bureaucratic hurdles and could be influenced by political considerations, affecting the impartiality of the judicial system.
The analysis of H.R. 8992, sponsored by Jamie Raskin, indicates no direct industry overlaps between the bill's subject matter and the sponsor's top donor industries. While there is significant lobbying activity in the policy area, the lack of direct financial ties to the bill suggests a low risk of conflict of interest. The lobbying expenditures, such as $120,000 from CEDIA, do not directly correlate with the bill's focus on certiorari petitions, which primarily concerns judicial processes rather than the interests of these lobbying entities. Voters should be aware that while lobbying exists, it does not appear to influence the sponsor's legislative intent significantly.
Organizations that lobbied on issues related to this bill's policy area.
| Client | Lobbying Firm | Amount |
|---|---|---|
| FRIENDS COMMITTEE ON NATIONAL LEGISLATION | FRIENDS COMMITTEE ON NATIONAL LEGISLATION | $1,000,000 |
| CEDIA | CEDIA | $120,000 |
| MINIMED GROUP, INC. | MEHLMAN CONSULTING, INC. | undisclosed |
| KNOA PHARMA LLC | MERCURY PUBLIC AFFAIRS, LLC | undisclosed |
| HELIX DEFENSE | CROSS POTOMAC CONSULTING LLC | undisclosed |
| SUR HOLDINGS | BGR GOVERNMENT AFFAIRS | undisclosed |
| GLOBAL KRATOM COALITION | BGR GOVERNMENT AFFAIRS | undisclosed |
| GIBSON, DUNN & CRUTCHER, LLP ON BEHALF OF CURATIVE INC. | BGR GOVERNMENT AFFAIRS | undisclosed |
| SEISMIC SOFTWARE, INC. | MILLER STRATEGIES, LLC | undisclosed |
| ALBERS AEROSPACE | BGR GOVERNMENT AFFAIRS | undisclosed |
| PALANTIR TECHNOLOGIES, INC. | AVOQ, LLC | undisclosed |
| RENAL CARE 360 | KILPATRICK TOWNSEND & STOCKTON | undisclosed |
| DEXCOM | BGR GOVERNMENT AFFAIRS | undisclosed |
| CITY OF PHILADELPHIA | BGR GOVERNMENT AFFAIRS | undisclosed |
| ORCA BIO | BGR GOVERNMENT AFFAIRS | undisclosed |
Source: Senate Lobbying Disclosure Act (LDA) filings, 2026
Top industries funding Jamie Raskin, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
